SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Arriagada R, Le Chevalier T, Quoix E, et al. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte Contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys. 1991; 20: 11831190.
  • 2
    Cox JD, Yesner RA. Causes of treatment failure and death in carcinoma of the lung. Yale J Biol Med. 1981; 54: 201207.
  • 3
    Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997; 350: 161165.
  • 4
    Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991; 83: 417423.
  • 5
    Perez CA, Bauer M, Edelstein S, et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys. 1986; 12: 539547.
  • 6
    Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998; 42: 19.
  • 7
    Armstrong J, Raben A, Zelefsky M, et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 1997; 44: 1722.
  • 8
    Patel RR, Mehta M. Three-dimensional conformal radiotherapy for lung cancer: promises and pitfalls. Curr Oncol Rep. 2002; 4: 347353.
  • 9
    Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering Committee. Radiother Oncol. 1999; 52: 137148.
  • 10
    Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995; 311: 899909.
  • 11
    Saunders MI, Rojas A, Lyn BE, et al. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. J Clin Oncol. 2002; 14: 352360.
  • 12
    Wilson EM, Williams FJ, Lyn BE, et al. Validation of active breathing control in patients with non-small-cell lung cancer to be treated with CHARTWEL. Int J Radiat Oncol Biol Phys. 2003; 57: 864874.
  • 13
    International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon beam therapy (ICRU Report 50). Bethesda, MD: International Commission on Radiation Units and Measurements; 1993.
  • 14
    Dische S, Warburton MF, Jones D, et al. The recording of morbidity related to radiotherapy. Radiother Oncol. 1989; 16: 103108.
  • 15
    Lee SW, Choi EK, Lee JS, et al. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003; 56: 9961004.
  • 16
    Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of Stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a Phase I/II trial. Int J Radiat Oncol Biol Phys. 2002; 54: 348356.
  • 17
    Sim S, Rosenzweig KE, Schindelheim R, et al. Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001; 51: 660665.
  • 18
    Bradley J, Movsas B. Radiation esophagitis: predictive factors and preventive strategies. Semin Radiat Oncol. 2004; 14: 280286.
  • 19
    Byhardt RW. The evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 1995; 32: 15131525.
  • 20
    Byhardt RW, Scott C, Sause WT, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1998; 42: 469478.
  • 21
    Bentzen SM, Dorr W, Anscher MS, et al. Normal tissue effects: reporting and analysis. Semin Radiat Oncol. 2003; 13: 189202.
  • 22
    Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000; 47: 112.
  • 23
    Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol. 2004; 22: 1922.
  • 24
    Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999; 45: 323329.
  • 25
    Graham MV, Purdy JA, Emami B, et al. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 1995; 33: 9931000.
  • 26
    Fowler JF, Chappell R. Non-small cell lung tumors repopulate rapidly during radiation therapy. Int J Radiat Oncol Biol Phys. 2000; 46: 516517.
  • 27
    Machtay M, Hsu C, Komaki R, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys. 2005; 63: 667671.
  • 28
    Belderbos JS, De Jaeger K, Heemsbergen WD, et al. First results of a Phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol. 2003; 66: 119126.
  • 29
    Maguire PD, Sibley GS, Zhou SM, et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys. 1999; 45: 97103.
  • 30
    Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a Phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005; 61: 318328.
  • 31
    Marks LB, Garst J, Socinski MA, et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective Phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol. 2004; 22: 43294340.
  • 32
    Rosenzweig KE, Fox JL, Yorke E, et al. Results of a Phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer. 2005; 103: 21182127.
  • 33
    Singh AK, Lockett MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2003; 55: 337341.
  • 34
    Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable Stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation Phase I trial. J Clin Oncol. 2004; 22: 43414350.
  • 35
    Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable Stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I/II trial. Cancer. 2001; 92: 12131223.
  • 36
    Willner J, Schmidt M, Kirschner J, et al. Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol) and 3D-conformal radiotherapy of Stage III inoperable non-small cell lung cancer. Results of a dose escalation study. Lung Cancer. 2001; 32: 163171.
  • 37
    Wolski MJ, Bhatnagar A, Flickinger JC, et al. Multivariate analysis of survival, local control, and time to distant metastases in patients with unresectable non-small-cell lung carcinoma treated with 3-dimensional conformal radiation therapy with or without concurrent chemotherapy. Clin Lung Cancer. 2005; 7: 100106.
  • 38
    Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005; 63: 324333.
  • 39
    Sibley GS, Mundt AJ, Shapiro C, et al. The treatment of Stage III nonsmall cell lung cancer using high dose conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1995; 33: 10011007.
  • 40
    Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2002; 52: 4957.